Join NCF for Oct2025. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=uCJWd8VLNsQ ABOUT A neuroendocrine cancer diagnosis can bring emotional, mental, and psychological challenges that are just as difficult as the physical ones. Join licensed clinical psychologist Dr. Karen Kersting from the Medical College of Wisconsin for a supportive discussion on Coping with Neuroendocrine Cancer: Managing Distress, Worry & Grief. She will offer insights and practical strategies to help patients and caregivers navigate the full emotional and psychological impact of living with NETs. ABOUT KAREN "REN" KERSTING Karen “Ren” Kersting, Ph.D. (she/her) Assistant Professor/Clinical Psychologist Medical College of Wisconsin Surgery/Surgical Oncology Karen Kersting, PhD, is a licensed clinical psychologist who provides counseling and psychotherapy to patients treated by surgeons in the Division of Surgical Oncology at the Medical College of Wisconsin. She completed an undergraduate degree in Journalism at the University of Wisconsin—Madison, a PhD in Counseling Psychology at Virginia Commonwealth University in Richmond, VA, and a postdoctoral fellowship in clinical health psychology at the Dayton Veterans Administration Medical Center in Dayton, OH. She joined the faculty of MCW in 2016. Dr. Kersting’s research interests include the development and assessment of integrated psychosocial services for people coping with cancer diagnosis and treatment, with an emphasis on patients diagnosed with cancer of the pancreas. Additionally, her work aims to highlight issues related to social determinants of health and Acceptance and Commitment Therapy interventions. SUBMIT YOUR QUESTIONS Submit your non-case specific questions for Dr. Kersting. T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 13: NET ONCOLOGY Download a Transcript of this Episode >> ABOUT THIS EPISODE Is it okay for NET patients to take “statin” medications to lower cholesterol or SSRI medication for depression? How often should full body scans be done? NET oncologist Dr. Jun Gong of Cedars-Sinai Medical Center addresses ten common questions you might ask your NET oncologist along your NET journey. MEET DR. JUN GONG Dr. Jun Gong is a medical oncologist of the Gastrointestinal Disease Research and Carcinoid and Neuroendocrine Tumors Group in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai. His primary clinical interests are in gastrointestinal (GI) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, and radiology. He is focused on translational and clinical cancer research in early therapeutic trials and biomarker development to improve patient outcomes in GI cancers. TOP 10 NET ONCOLOGY QUESTIONS 1. Which is better -- if the tumor is expressing somatostatin on its receptors by DOTATATE scan or biomarker in tissue biopsy? 2. Since the somatostatin analogues bind to somatostatin receptors, can NET patients take “statin” medications for high cholesterol? 3. Is there a link between psychiatric medications and NETS? Can someone with NET take selective serotonin receptor inhibitors SSRI or SNRI? 4. What is the difference between genetic and genomic testing? When would you do genetic screening/testing and when would you do genomic testing/tumor sequencing? 5. Is it possible to find NET markers on serum or blood by using mass spectrum without biopsies? Is there a promising liquid biopsy? 6. How often should full body scans be done to discover metastases to other body parts? 7. Can well differentiated tumors become poorly differentiated? 8. Can NETs produce multiple hormones? Should one try to control any production of any hormones for general prevention? Should we control serotonin production generally? 9. How aggressive should you be to seek out new treatments when tumor burden is stable? (Some patients want to get rid of tumors so side effects of tumors are lessened.) 10. How common is having issues with liver functionality? What are the signs of liver failure due to tumor burden? DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

ACTION-1: Alpha PRRT with Ac-225 in GEP-NETs << Back ACTION-1 ALPHA PRRT - Study of RYZ101 Compared With SOC in Pts With Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy CLINICALTRIALS.GOV IDENTIFIER: NCT05477576 DRUG/TREATMENT: ALPHA PRRT with 225Ac-DOTATATE Actinium 225 radiolabeled somatostatin analog (SSA) for injection COMPARED TO: Everolimus, Sunitinib, Octreotide, Lanreotide PHASE: Phase 3 STATUS: Recruiting April 2023 SPONSOR: RayzeBio, Inc. https://www.youtube.com/watch?v=U_cjeFdRZwk Dr. Heloisa Soares discusses the ACTION-1 Trial https://www.youtube.com/watch?v=w9kA8_gmVfM Dr. Will Pegna discusses the ACTION-1 Trial Starting at 5:07 DESCRIPTION: RayzeBio is sponsoring the ACTION-1 study, a phase 3 open-label study of 225Ac-DOTATATE (RYZ101) compared with standard of care therapy in patients with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following treatment with 177Lu-DOTATATE/TOC. Update - Aug 22, 2023 2023 ESMO Abstract shows preliminary safety and efficacy (Note: The meaning of efficacy in clinical trials refers to the capacity of a treatment, device, or medication, to produce a desired effect on the patient population.) Download the PDF here: 1198P-RYZ101-301-ESMO-2023-poster-UPLOAD .pdf Download PDF • 4.57MB For more information on eligibility criteria, trial locations, study details, etc ., go to ClinicalTrials.gov to view this trial here. OTHER HELPFUL RESOURCES: 'Alpha Radioligand Therapy in Neuroendocrine Neoplasms: Current Landscape and Spotlight on RYZ101' CONTACT: RayzeBio Clinical Trials EMAIL: clinicaltrials@rayzebio.com PHONE: 619-657-0057

<< Go back to the Podcast page EPISODE 36: NEN TREATMENTS: FOCUS ON IMMUNOTHERAPY Download a Transcript of this Episode >>> ABOUT THIS EPISODE What is immunotherapy? How effective are they for neuroendocrine neoplasms (NENs)? Dr. Jennifer Eads from Penn Medicine answers common questions about immunotherapy. She discusses the latest in CAR T therapy, DLL3, and vaccine therapy for NENs. MEET DR. JENNIFER EADS Dr. Jennifer Eads is an associate professor of medicine at the University of Pennsylvania, Abramson Cancer Center where she is a gastrointestinal medical oncologist focusing on the treatment of and research in patients with neuroendocrine tumors and gastroesophageal cancers. She is the Physician Lead for GI Clinical Research, overseeing the Penn GI clinical research portfolio. She is the Penn institutional principal investigator for the Eastern Cooperative Oncology Group (ECOG-ACRIN) and serves as the Director of the National Clinical Trials Network (NCTN) for the Abramson Cancer Center. She has served as principal investigator for multiple phase I/II/III clinical trials, including as the national study chair for multiple cooperative group trials. She has served on the National Clinical Cancer Network (NCCN) neuroendocrine tumors guidelines committee, is a former member of the North American Neuroendocrine Tumor Society (NANETS) Board of Directors and is currently on the Board of Scientific Advisors for the Neuroendocrine Tumor Research Foundation (NETRF). In 2022, she was named as the ECOG-ACRIN Young Investigator of the Year. TOP TEN QUESTIONS ABOUT NEN TREATMENTS: What is immunotherapy? How does it work? How does immunotherapy differ from other treatments? When is immunotherapy used? Which neuroendocrine cancers are they used for? What are the various immunotherapy drugs used for neuroendocrine cancer and how do they work? What are immune checkpoint inhibitors? What is CAR-T therapy? What is DLL3? What is vaccine therapy? What side effects might someone have when taking immunotherapy? How does it make me look (will I lose my hair)? How will it make me feel (will I be able to work)? Does immunotherapy cause someone to be immunocompromised? What monitoring needs to be done while on immunotherapy? How do you decide when to use immunotherapy, which to use, and for what patient? What do you see as the future of immunotherapy in neuroendocrine cancer treatment? RESOURCES Immunotherapy Trials for NENs Clinical trials mentioned in this episode: CHM-2101 CAR-T cell for GI Cancers DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum WATCH https://www.youtube.com/watch?v=oSqUgq6QdnM https://www.youtube.com/watch?v=_sVqHnTs-Sk DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Calls to Action Every question you’ve asked, every challenge you’ve faced, and every choice you’ve made along the way holds meaningful insight. Patients and caregivers don’t just navigate care — you influence it. Your voice helps researchers, clinicians, and advocates better understand what matters most, what’s working, and what must change. By sharing your perspectives, you play an active role in moving neuroendocrine cancer care forward. You help ensure that future treatment decisions, support resources, and research priorities reflect the real needs of the people living this journey every day. Your lived experience is powerful — and it deserves to be heard. Take action. Disclaimer: Some of the studies and opportunities listed on this page may be sponsored or supported by pharmaceutical or industry partners. These are shared to support research and improve understanding of neuroendocrine cancer. They are not intended as marketing or for the purpose of selling any product or service. Participation is always voluntary, and we encourage you to discuss any questions with your healthcare team. CURRENT OPPORTUNITIES Reimbursed Research: Carcinoid Syndrome LDA Research Ltd is an independent healthcare market research company conducting research on behalf of a pharmaceutical company. We are seeking to speak with adults in the United States who are living with Carcinoid Syndrome. The purpose of this research is to better understand the patient journey, treatment experiences, symptom management, and the day- to-day impact of living with Carcinoid Syndrome. Insights gathered will help improve understanding of patient experiences and unmet needs. We were hoping you may be able to forward this to your members or any interested parties. Please let me know if you need any further information. What does participation involve? Participants may be invited to take part in one of the following: A 60-minute online interview at a time convenient for you, with an honorarium of $100 upon completion; or A 2-hour online focus group, with an honorarium of $200 upon completion. Any honorarium will be provided following participation within 15 working days. Participation is entirely voluntary. All responses will remain strictly confidential and anonymous. This is a non-promotional market research study, and no identifying information will be shared with the sponsoring pharmaceutical company. The study has been designed in accordance with industry research standards, including relevant MRS, BHBIA, GDPR, and HIPAA requirements. Any personal information collected will be used solely for the purposes of conducting this research. Interested in taking part? If you would like to see whether you qualify, please complete a short screening questionnaire using the link below: https://ldaresearch.questionpro.eu/t/AB3vBHcZB3wnLd Take the Survey Are you and your partner facing cancer and its financial challenges? Are you and your partner facing cancer and its financial challenges? Researchers at the University of Maryland are looking for couples dealing with cancer to participate in a research study examining how financial challenges related to cancer affect couples' health. Findings from this study will help better understand the experiences of patients and their partners and support the development of an intervention aimed at helping couples cope with the financial impact of cancer. What the study involves: If you choose to participate, you will be asked to complete a screening survey to assess your eligibility. If eligible, the survey will ask for your and your partner's email addresses so we can send a brief anonymous survey that will take approximately 15–20 minutes to complete. You may be eligible if you: Are 18 years or older Are in a committed relationship and have lived with your partner You or your partner have received cancer treatment within the past 5 years Reside in the United States Can read and understand English You and your partner both consent to participate Please note: Individuals whose only cancer diagnosis is non-melanoma skin cancer or unspecified skin cancer are not eligible to participate. Each partner will receive a $15 gift card and will also be entered into a drawing to win one of two $100 gift cards. If you are interested in participating or have any questions, please contact znbazizi@umd.edu or access the screening survey here. Take the Survey NET Experience Survey If you are living with or caring for someone living with neuroendocrine tumors (NETs), we invite you to share your experiences through an online survey. While there is no compensation for completing this survey, your responses will help us better understand the needs of people living with NETs. The survey will take 3-5 minutes to complete, and your answers will remain anonymous. We thank you for considering participating in this survey. Your responses are impactful. Take the Survey CLOSED Study by Researchers at the University of Alabama at Birmingham (IRB-300015226-002) February, 2026 Researchers at the University of Alabama at Birmingham (UAB) are conducting an anonymous, IRB-approved survey to better understand how patients experience conversations about cancer surgery, including whether what matters most to patients is addressed during treatment decision-making. The goal of this study is to help inform more patient-centered communication and improve how patients are supported when making treatment decisions. Important note: When asked to select the option that best reflects your primary tumor site, neuroendocrine cancer / neuroendocrine tumor (NET) / neuroendocrine carcinoma is not listed as a separate category. Please select “Other” and, in the open-text field, note “Neuroendocrine tumor” or “Neuroendocrine cancer.” People with all types of neuroendocrine cancers are welcome to participate, including well-differentiated NETs, neuroendocrine carcinoma, pheochromocytoma, and paraganglioma. Who can participate: Adults diagnosed with cancer within the past 2 years Have met with a surgeon to discuss possible cancer surgery Time commitment: About 10 minutes Anonymous and voluntary Your perspective can help improve patient-centered communication for future patients. Take the survey here: https://uab.co1.qualtrics.com/jfe/form/SV_1OmDi6x2VzojfmK Take the Survey Diagnosed with Insulinoma? Market Research Opportunity November, 2025 We are seeking individuals diagnosed with insulinoma to participate in an important research study. The goal of this project is to better understand the real-life experiences of people living with insulinoma — especially how hypoglycemia affects daily life, routines, relationships, and well-being. What Participation Involves Participants will take part in a one-hour confidential interview with Mike Reilly, an experienced and independent market research professional with extensive knowledge of insulinoma. Mike is dedicated to creating a respectful, comfortable experience, and all information shared will remain strictly anonymous. Compensation and Donation As a thank-you for your time: - Participants will receive a $250 honorarium - OLG Research will donate an additional $100 to the Neuroendocrine Cancer Foundation for each completed interview Interested in Participating? Please contact Nicole Maurer at OLG Research: Email: nmaurer@olgresearch.com Phone: +1-973-575-0019 Email Could YOU be in Crinetics' Next Carcinoid Syndrome Patient Leadership Council? December, 2025 Your experiences matter—and they can help shape the future of treatment. NCF is sharing an opportunity to participate in the Crinetics Patient Leadership Council, a small group of patients and care partners who meet virtually throughout the year to share insights about living with rare disease. Council members provide input on the patient journey, treatment experiences, educational needs, and how clinical trials are designed and communicated. The Council will consist of 8–10 patients or care partners who meet virtually 3–4 times per year, with the possibility of additional meetings as needed. Members commit to a one-year term (with the option to extend to two years) and are compensated for their time. All conversations are respectful, confidential, and focused on ensuring patient perspectives guide meaningful progress. Interested in learning more or applying? This is a chance to turn your lived experience into impact and help improve care for others. Interested in learning more or applying? Visit the Crinetics PLC Page Download Flyer VOICE epNEC Care Partner Survey February, 2026 We invite you to take part in an online survey to better understand your role as a care partner/caregiver in supporting an individual with neuroendocrine carcinoma. We want to learn more about the challenges you encounter while providing care and the areas where care and support can be improved. If you are interested, please click on the link or scan the QR code below to enter your email address: https://s-hab.medefield.com/wix/p294869318978.aspx We’ll send you a short questionnaire to confirm your eligibility, along with an informed consent form that explains the study in more detail. If you qualify and choose to participate, you will be directed to the full survey. Upon completing the survey, you will receive an honorarium as a thank-you for your time and contribution. Please note: The survey will come from Paradigm Sample (invite@decipherinc.com ) within 2-3 days. Please keep an eye on your inbox and check your spam or junk folder just in case. Your email will be used solely for the purpose of sending the survey invitation and will be deleted after the study concludes. Your information will be kept strictly confidential. Thank you for considering taking part in this important study. Download Flyer VOICE epNEC Patient Survey November, 2025 People living with neuroendocrine carcinoma (epNEC) are invited to share their experiences through an online research survey. Patient insights will help inform future care, resources, and support for the neuroendocrine cancer community. If you are interested, click the link below (or scan the QR code) to enter your email address. You will receive a brief eligibility questionnaire and additional study details. If eligible, you will be invited to complete the full survey. Sign up here >>> Survey invitations will be sent from invite@decipherinc.com within 2–3 days. Please check your spam or junk folder if needed. Your email will be used only to send the survey invitation and will be deleted after the study concludes. Thank you for considering taking part in this important study. Download Flyer Have You been Treated With AlphaMedix™? November, 2025 We’re looking for patients who would like to share their experiences in a one-hour, one-on-one interview with a company that wants to better understand the patient journey. No preparation needed An opportunity to share your story Participants will be compensated at fair market value Your voice and experience matter! Interested in Participating? Please contact Lisa Yean, Director of Programs and Outreach at NCF: Email: Lisa@NCF.net Email

CHM-2101 CAR-T cell for GI Cancers << Back A Phase 1 / 2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy IDENTIFIER ( ClinicalTrials.gov ) : NCT06055439 DRUG/TREATMENT : CHM-2101 CAR-T Cells PHASE : 1/2 STATUS : Recruiting SPONSOR : Chimeric Therapeutics DESCRIPTION: Chimeric Therapeutics is sponsoring a Phase 1/2 open-label study to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced G1, G2, and well-differentiated G3 neuroendocrine tumors of the midgut and hindgut (ileal, jejunal, cecal, distal colonic, or rectal; with ≤ 55% Ki67 expression) that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting. Phase 1 involves dose escalation and expansion. The recommended Phase 2 dose will be based on results from the Phase 1. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Jason B. Litten, MD EMAIL: jlitten@chimerictherapeutics.com PHONE: 415-802-4360 RELATED RESOURCES Chimeric Therapeutics Announces FDA Clearance of IND Application for CHM 2101, A Novel CDH17 CAR T Cell Therapy for Advanced Gastrointestinal Cancers

NET Testing < Back to Topics Play Video Play Video 18:28 06. NET Testing: The What, When, How and Why (Dr. Namrata Vijayvergia) - 2022 LACNETS Conference Dr. Neena Vijayvergia addresses the what, when, how and why of NET testing. Presenter: Namrata Vijayvergia, MD Medical Oncologist, Fox Chase Cancer Center 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 35:16 "Understanding NET Diagnosis" with Dr. Chandrasekharan • 2024 #LACNETS Patient Conference 2. "Understanding NET Diagnosis" with #Dr.Chandrasekharan Our 2024 LACNETS Neuroendocrine Tumor Patient Conference is designed for neuroendocrine cancer (NET) patients and caregivers to deepen your understanding of NETs. Whether you are newly diagnosed or have been living with NET for many years, we encourage you to attend: - Learn from top NET experts from across North America on a range of topics relevant to the NET patient journey. - Topics include work-ups, scans, surgery, carcinoid crisis, liver-directed therapy, PRRT, systemic treatments, treatment sequencing, NET guidelines, and clinical trials. - Gain insight into NET decision-making through the NET tumor board panel discussion. - Hear stories from NET patients and caregivers. - Join virtually, where you can pause, rewind, or replay. - There is no cost to attend. This event is made possible by the generosity of donors and sponsors. #LACNETS #neuroendocrinecancer #clinicaltrials #lungcancer #NETcancer #Letstalkaboutnets For more information, visit LACNETS.org. < Back to Topics Next Topic >

Join NCF for Jan2026. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=Vb7aH06UWrE Download PowerPoint Slides >>> Some Topics Covered: Types of Functional Neuroendocrine Tumors, Hormone-producing, Carcinoid Syndrome, Insulinoma, Gastrinoma, VIPoma, Zollinger-Ellison syndrome (ZES), Diarrhea, Flushing, Hypoglycemia, Carcinoid Heart Disease, Cushing Syndrome, Somatostatinoma. ABOUT Join us for an easy-to-understand overview of functional neuroendocrine tumors (NETs) with Dr. Jaydira Del Rivero, a medical oncologist and endocrinologist at the National Cancer Institute. Functional NETs can cause the body to produce too many hormones, leading to challenging symptoms such as low blood sugar (often seen in insulinoma), high blood sugar (glucagonoma), carcinoid syndrome (excess serotonin), and other hormone-related issues and symptoms. Dr. Del Rivero will explain what these syndromes are, how they’re diagnosed, and the latest updates in treatment. She will also discuss conditions that can occur because of NETs or their treatments. She will help patients understand why symptoms like hypoglycemia are more common in some NET types. Whether you’re a patient, caregiver, or simply want to better understand functional NETs, this webinar will offer practical, up-to-date information to help you feel more informed and empowered. ABOUT DR. JAYDIRA DEL RIVERO Medical Oncologist & Endocrinologist National Cancer Institute, National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. THANKS TO OUR SPONSORS PRESENTING SPONSOR SPONSORS T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

A Study of ZL-1310 in Participants With Selected Solid Tumors << Back A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors IDENTIFIER ( ClinicalTrials.gov ) : NCT06885281 DRUG/TREATMENT : ZL-1310 PHASE : 1/2 STATUS : Recruiting SPONSOR : Zai Lab (Shanghai) Co., Ltd. https://www.youtube.com/watch?v=RQF3krrFx_g ZL-1310 in Participants With Selected Solid Tumors .pdf Download PDF • 1.98MB DESCRIPTION: This is an open-label, multi-center Phase Ib/II study testing a new targeted treatment called ZL-1310 in selected solid tumors, including gastrointestinal and pancreatic poorly differentiated neuroendocrine carcinomas (GEP NECs) and other high-grade neuroendocrine carcinomas. What is ZL-1310? ZL-1310 is a novel antibody-drug conjugate (ADC) designed to target a protein called DLL3, which is commonly found on the surface of many neuroendocrine cancers. DLL3 is considered a new and promising treatment target, especially in GEP NECs. ADCs work by combining: an antibody, which seeks out cancer cells with a specific marker (like DLL3), and a drug payload, often a chemotherapy molecule, that is delivered directly to those cells. About This Study (NCT06885281) This trial is now enrolling patients to evaluate: Safety and side effects of ZL-1310 How well the drug works in DLL3-positive neuroendocrine carcinomas How the drug behaves in the body Optimal dose levels for future studies Who Can Join (Key Inclusion Criteria) This study includes two main groups of patients: Cohort 1: People with advanced GEP NECs (including cancers of the esophagus, stomach, pancreas, gallbladder/hepatobiliary system, or colon/rectum) Must have received 1–2 prior chemotherapy or other treatment regimens Cohort 2: People with other advanced NECs or solid tumors that express DLL3 Must have received 1–2 prior treatment regimens Additional notes for patients: DLL3 testing is not required before enrolling for GEP NECs or other NECs Previous treatment with other DLL3-targeted therapies is allowed For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: ZaiLab_1310-002_StudyTeam EMAIL: Zailab_1310-002_StudyTeam@zailaboratory.com PHONE: 86 021-61632588 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

<< Go back to the Podcast page EPISODE 14: PALLIATIVE CARE Download a Transcript of this Episode >> ABOUT THIS EPISODE What is palliative care and how does this relate to NET? Palliative care physician Dr. Chandana Banerjee of City of Hope shares insights and tips on communication, coping, and managing grief and loss. MEET DR. CHANDANA BANERJEE Chandana Banerjee, M.D., M.P.A., HMDC, is the Dean, Director and designated institutional official for Graduate Medical Education at City of Hope. She is also an assistant clinical professor in the Department of Supportive Care Medicine , specializing in hospice and palliative care. She developed the City of Hope Hospice & Palliative Medicine Fellowship . She also established the Cancer Pain Rotation for Kaiser Permanente Los Angeles Hospice & Palliative Medicine Fellowship, which is now part of the core curriculum for the Kaiser Permanente Southern California Hospice & Palliative Medicine fellowship program. Dr Banerjee also developed and directed the End of Life Symposium , which was first held at City of Hope in September 2019 and was endowed by Arthur Riggs, Ph.D. She is the physician lead for Schwartz Rounds at City of Hope and serves as chair on the End of Life Option Act Subcommittee. She is also a member of the Continuing Medical Education and the Ethics and Quality of Life committees. She co-founded the City of Hope Expressions of Hope initiative in partnership with Diversity, Equity and Inclusion. Learn more about Dr. Banerjee and her background here. TOP 10 PALLIATIVE CARE QUESTIONS 1. What is palliative care? How is it different from hospice? 2. Who should be in palliative care? Who should not be in palliative care? 3. How does someone ask for palliative care? 4. Give an example of how palliative care can help someone living with NET. 5. What does coping with a cancer diagnosis look like? What suggestions do you have to help with coping? 6. What advice do you have for NET caregivers? 7. What insights or advice do you have to help with communication between NET patients and providers? NET patients and their loved ones? 8. What does end-of-life care planning look like? When should it begin? 9. What does the end of life look like for NET patients? 10. How can one manage grief and loss related to the cancer diagnosis? Click here for Caregiver Resources >> DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs << Back Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs IDENTIFIER ( ClinicalTrials.gov ) : NCT07165132 DRUG/TREATMENT : RYZ401 PHASE : 1 STATUS : Recruiting soon SPONSOR : Rayzebio DESCRIPTION: This clinical trial is testing a new treatment called RYZ401 in people with certain neuroendocrine tumors (NETs) and other solid tumors that have a protein on their cells called SSTR (somatostatin receptor). RYZ401 is an investigational (not yet approved) drug — meaning this study is meant to learn how safe it is and whether it may help treat these cancers. Who Can Join Adults aged 18 or older with a confirmed NET or other SSTR-positive cancer (such as certain neuroendocrine tumors or related solid tumors) may be eligible. What Will Happen During the Study The study includes a dose-finding (dose escalation) phase and a dose-expansion phase. Participants will receive RYZ401 and be monitored carefully for safety, side effects, and how their body handles the drug. Researchers will also look for early signs of benefit — for example, whether the tumor shrinks or stops growing. Why This Study Matters If RYZ401 proves to be safe and effective, it could become a new treatment option for patients with neuroendocrine tumors or other SSTR-positive cancers — especially those who may not have many other treatment choices. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT Name: RayzeBio Clinical Trials Phone Number: +1 619-657-0057 Email: clinicaltrials@rayzebio.com This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

DAREON®-NEC-1: Obrixtamig Plus Chemotherapy vs Standard Chemotherapy in Advanced epNEC << Back DAREON ®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy IDENTIFIER ( ClinicalTrials.gov ) : NCT07544654 DRUG/TREATMENT : Obrixtamig , Carboplatin , Etoposide PHASE : 3 STATUS : Recruiting SPONSOR : Boehringer Ingelheim A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary (outside of the lungs) Neuroendocrine Carcinomas https://www.youtube.com/watch?v=SjABtPcGEds In this video, Udhayvir Grewal, MD, a gastrointestinal and neuroendocrine medical oncologist at Winship Cancer Institute of Emory University, explains the DAREON™-NEC1 clinical trial for patients with advanced DLL3-positive extrapulmonary neuroendocrine carcinoma (NEC). DESCRIPTION: This study is open to adults with advanced extrapulmonary neuroendocrine cancer. The purpose of this study is to find out if a study medicine called obrixtamig plus standard chemotherapy (carboplatin and etoposide) improves survival when compared to standard chemotherapy (carboplatin and etoposide) alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker delta-like ligand 3 (DLL3). Participants are put into 2 groups randomly, which means by chance. One group (treatment arm) receives obrixtamig and standard chemotherapy followed by obrixtamig alone for up to 3 years. The other group (control arm) receives standard chemotherapy without obrixtamig for about 4 months. All treatments are given as infusions into a vein. During the study, participants in both groups visit the study site regularly. Participants in the treatment arm stay overnight at the study site following the first 2 obrixtamig treatments. The doctors regularly check participants' health and take note of any unwanted effects. At some of the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works. For more information on eligibility criteria, trial locations, and study details, go to ClinicalTrials.gov to view this trial here. CONTACT Name: Boehringer Ingelheim Phone Number: 1-800-243-0127 Email: unitedstates@bitrialsupport.com This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.